B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation

Assistance Publique - Hôpitaux de Paris60 enrolled

Overview

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have a persistent deficit in humoral immunity up to one year post-transplant. To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT patients is still hampered by the fact that post-transplant regenerative hematopoiesis has never been studied, and more generally by our currently limited knowledge on the development and function of human B lymphocytes. The main objective of our study is to study early B-cell progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hematologic Malignancy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients : * 18 years of age and older * with hematological malignancies and subject to allogeneic HSCT * with health insurance coverage (bénéficiaire ou ayant droit) * having signed a written informed consent. Inclusion criteria of donor * 18 years of age and older * with health insurance coverage (bénéficiaire ou ayant droit) * having signed a specific written informed consent. Exclusion criteria of recipient and donor * Absence of written informed consent * Patient or donor on AME * Patient or donor on AME or under protection by law, tutorship or curatorship * Pregnant women

Outcomes

Primary Outcomes

Secondary Outcomes

B cells reconstitution

B cell clusters as assess by CyTOF technology

Time frame: at 6 months post-transplant

Perturbations in growth or differentiation of progenitor/precursor of B cells

Perturbations in growth or differentiation of progenitor/precursor of B cells will be assessed by cytometry technology

Time frame: at 100 days post transplant